Entrada Therapeutics, Inc. TRDA
4.74 USD -0.37 (-7.24%)
Nov 3, 2026, 3:20 PM EST
4.62 Day range 5.08
4.37 52-week range 16.03
- YTD
- -53.89%
- 1 year
- -30.09%
Financial health
Altman Z-Score
-0.80 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
B-2 / 5 overall
- DCF 4
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 4
Valuation
P/E -3.0×
FY 2019 5y median -4.8× FY 2025
P/S 16.7×
FY 2019 5y median 3.1× FY 2025
P/B 1.4×
FY 2019 5y median 1.8× FY 2025
P/FCF -3.3×
FY 2019 5y median -4.4× FY 2025
EV/EBITDA -2.8×
FY 2019 5y median -2.8× FY 2025
EV/Sales 15.2×
FY 2019 5y median 2.9× FY 2025
FCF Yield -30.5%
FY 2019 5y median -10.4% FY 2025
Profitability
Gross Margin 83.9%
FY 2019 5y median 83.9% FY 2025
Operating Margin -613.7%
FY 2019 5y median 0.0% FY 2025
Net Margin -565.5%
FY 2019 5y median 0.0% FY 2025
ROE -47.0%
FY 2019 5y median -17.1% FY 2025
ROIC -43.7%
FY 2019 5y median -17.1% FY 2025
ROA -38.1%
FY 2019 5y median -16.7% FY 2025
Growth (YoY)
Revenue -87.9%
FY 2019 FY 2025
Operating Income -431.8%
FY 2019 FY 2025
EPS (diluted) -306.5%
FY 2019 FY 2025
Free Cash Flow -189.7%
FY 2019 FY 2025
Financial Health
Current Ratio 12.5×
FY 2019 5y median 11.1× FY 2025
Quick Ratio 12.5×
FY 2019 5y median 11.1× FY 2025
Debt / Equity 0.2×
FY 2019 5y median 0.1× FY 2025
Net Debt / EBITDA 0.3×
FY 2019 5y median 0.2× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31